Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of SKB264 plus pembrolizumab in selected solid tumors
CTR20223165Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, pembrolizumab in Cervical Cancer (CC), transitional cell carcinoma (TCC), ovarian cancer, prostate cancer (PCa), endometrial cancer (EC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Feb 2023; status: active.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
Cervical Cancer (CC)transitional cell carcinoma (TCC)ovarian cancerprostate cancer (PCa)endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20223165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223165.